ANIK - Anika Therapeutics Inc Stock Price, Fair Value and News

$14.21+0.18 (+1.28%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

ANIK Price Action

Last 7 days

3.6%

Last 30 days

-7.8%

Last 90 days

-12.4%

Trailing 12 Months

-45.2%

ANIK RSI Chart

ANIK Valuation

Market Cap

201.4M

Price/Earnings (Trailing)

-3.57

Price/Sales (Trailing)

1.68

EV/EBITDA

35.39

Price/Free Cashflow

-86.42

ANIK Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

ANIK Fundamentals

ANIK Revenue

Revenue (TTM)

119.9M

Rev. Growth (Yr)

-6.54%

Rev. Growth (Qtr)

-7.56%

ANIK Earnings

Earnings (TTM)

-56.4M

Earnings Growth (Yr)

65.29%

Earnings Growth (Qtr)

26.92%

ANIK Profitability

EBT Margin

-2.31%

Return on Equity

-36.62%

Return on Assets

-27.81%

Free Cashflow Yield

-1.16%

ANIK Investor Care

Buy Backs (1Y)

4.54%

Diluted EPS (TTM)

-3.83

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	120.6M	120.3M	120.1M	119.9M
2023	115.6M	117.3M	119.1M	120.8M
2022	150.2M	151.7M	152.4M	113.8M
2021	129.4M	136.8M	144.7M	147.8M
2020	125.3M	125.5M	127.5M	130.5M
2019	109.0M	108.9M	111.8M	114.6M
2018	111.3M	108.4M	108.0M	105.6M
2017	104.5M	111.4M	112.8M	113.4M
2016	99.8M	103.4M	105.5M	103.4M
2015	87.1M	83.7M	85.4M	93.0M
2014	93.8M	99.3M	103.6M	105.6M
2013	72.2M	73.4M	76.4M	75.1M
2012	67.4M	70.9M	67.2M	71.4M
2011	54.8M	56.5M	61.1M	64.8M
2010	0	45.3M	50.4M	55.6M
2009	0	0	0	40.1M

Get all data in R, Python etc through our Historical Stock Data APIs

About Anika Therapeutics Inc

Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and bone preserving joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products includes Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; Cingal, a single-injection OA pain management product to provide both short- and long-term pain relief; and Hyvisc, a molecular weight injectable HA veterinary product. The company's joint preservation and restoration product family comprises 150 bone preserving joint technology products, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants, which are designed to treat upper and lower extremity orthopedic conditions; sports medicine solutions used to repair and reconstruct damaged ligaments and tendons; and orthopedic regenerative solutions, including Hyalofast and Tactoset. In addition, it offers non-orthopedic products comprising HA-based products for non-orthopedic applications including adhesion barrier, advanced wound care, ear, nose, and throat products, as well as ophthalmic products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.

CEO	Dr. Cheryl Renee Blanchard Ph.D.
WEBSITE	anikatherapeutics.com
SECTOR	Healthcare
INDUSTRY	Medical Devices
EMPLOYEES	345

Anika Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Anika Therapeutics Inc? What does ANIK stand for in stocks?

ANIK is the stock ticker symbol of Anika Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Anika Therapeutics Inc (ANIK)?

As of Tue Apr 22 2025, market cap of Anika Therapeutics Inc is 201.44 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ANIK stock?

You can check ANIK's fair value in chart for subscribers.

Is Anika Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether ANIK is over valued or under valued. Whether Anika Therapeutics Inc is cheap or expensive depends on the assumptions which impact Anika Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ANIK.

What is Anika Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 22 2025, ANIK's PE ratio (Price to Earnings) is -3.57 and Price to Sales (PS) ratio is 1.68. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ANIK PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Anika Therapeutics Inc's stock?

In the past 10 years, Anika Therapeutics Inc has provided -0.094 (multiply by 100 for percentage) rate of return.